(CEPH), West Chester, Penn.
(CHIR), Emeryville, Calif.
Robertson, Stephens analyst Mark Simon advised investors to buy CEPH on weakness following a
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury